Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Earnings

Veru Inc. Sets Date for 2025 Financial Report Release

Robert Sasse by Robert Sasse
December 12, 2025
in Earnings, Healthcare, Pharma & Biotech
0
Veru Stock
0
SHARES
36
VIEWS
Share on FacebookShare on Twitter

Veru Inc. has officially scheduled the release of its 2025 financial results. The report will be issued on Wednesday, December 17, 2025, at 8:00 AM Eastern Time, prior to the market opening. Following the publication, the company’s leadership will host a conference call accompanied by an audio webcast.

This financial disclosure coincides with a significant scientific presentation by the company. Veru is currently showcasing clinical data this week at the 18th International Conference on Sarcopenia, Cachexia, and Wasting Disorders, which runs from December 11 to 13. The proximity of these events places both clinical progress and financial health in the spotlight for investors simultaneously.

Key Details for Investors

  • Earnings Release Date: December 17, 2025
  • Release Time: 8:00 AM ET (Pre-market)
  • Follow-up Event: Management conference call and audio webcast
  • Recent Corporate Event: Clinical data presentation at an industry conference (December 11-13)
  • Recent Share Price: Closed at $2.56 on December 11
  • Market Capitalization: Approximately $41.09 million as of December 11

Institutional Positioning and Report Significance

Recent regulatory filings reveal notable shifts in institutional ownership during the third quarter of 2025. The Vanguard Group reported acquiring an additional 640,687 shares, while Millennium Management increased its stake by 231,602 shares. These movements highlight changing investor sentiment, though they do not serve as a direct indicator of the upcoming quarterly performance.

Should investors sell immediately? Or is it worth buying Veru?

The pre-market earnings release allows the investment community to digest the financial figures without the influence of intraday trading volatility. The subsequent call will provide crucial context, offering management commentary on operational metrics, liquidity, and the overall business trajectory. For a company at this stage, these combined elements deliver essential guidance.

Looking Ahead to December 17

All eyes will be on the consolidated results when they are published at 8:00 AM ET on December 17. The revenue, earnings, and liquidity details contained within will be critical for assessing whether the company’s financial trajectory aligns with the promising clinical updates shared just days prior. The management discussion will further clarify the path forward as Veru navigates its development phase.

Ad

Veru Stock: Buy or Sell?! New Veru Analysis from March 25 delivers the answer:

The latest Veru figures speak for themselves: Urgent action needed for Veru investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 25.

Veru: Buy or sell? Read more here...

Tags: Veru
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Gossamer Bio Stock
Analysis

Gossamer Bio’s Pivotal FDA Meeting Looms in June 2026

March 25, 2026
BioNano Genomics Stock
Analysis

BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds

March 25, 2026
Humacyte Stock
Analysis

Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts

March 25, 2026
Next Post
Barrick Mining Stock

Barrick Gold Shares Surge to Annual High on Strong Fundamentals

Omv Stock

OMV's Strategic Gamble: Paying a Premium for Future Stability

CureVac Stock

CureVac Acquisition Finalized as BioNTech Secures Controlling Stake

Recommended

Nike Stock

Nike Faces Critical Test as Quarterly Results Approach

6 months ago
Opendoor Stock

Opendoor Shares Plunge as Investor Confidence Evaporates

4 months ago
QuantumScape Stock

QuantumScape’s Stock Under Pressure: Can Innovation Outpace Market Doubts?

4 months ago
NASDAQ 100 Stock

Tech Giants Face Reality Check as AI Costs Rattle Nasdaq 100

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Regulatory Scrutiny and Price Wars Threaten Fair Isaac’s Dominance

Figma Embraces Third-Party AI to Power Its Design Ecosystem

BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds

Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts

Evolent Health Bets on AI Leadership Amid Share Price Decline

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

Trending

Dell Stock
AI & Quantum Computing

Dell’s Quantum Security Push Amidst AI-Driven Growth

by Kennethcix
March 25, 2026
0

Dell Technologies is fortifying its hardware portfolio for the dual challenges of quantum computing and artificial intelligence....

Gossamer Bio Stock

Gossamer Bio’s Pivotal FDA Meeting Looms in June 2026

March 25, 2026
SOXX ETF Stock

Semiconductor Sector Faces Supply Chain Strain Amid Helium Shortage Concerns

March 25, 2026
Fair Isaac Stock

Regulatory Scrutiny and Price Wars Threaten Fair Isaac’s Dominance

March 25, 2026
Figma Stock

Figma Embraces Third-Party AI to Power Its Design Ecosystem

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Dell’s Quantum Security Push Amidst AI-Driven Growth
  • Gossamer Bio’s Pivotal FDA Meeting Looms in June 2026
  • Semiconductor Sector Faces Supply Chain Strain Amid Helium Shortage Concerns

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com